Development

Cerevance raising $60m for brain disease drug discovery

Company awaits Phase 2 trial readout for new Parkinson’s drug as part of its mission to combat brain disease. In the world of Longevity start-ups,...

Indication expansion to meet Longevity market demand

Several compounds have demonstrated life-extending effects in animal models, some of which are currently being tested for their ability to exert anti-aging effects in...

Alkahest Parkinson’s clinical trial gets funding boost

Alkahest announced today that they have initiated a phase 2 clinical trial with funding from the Michael J. Fox Foundation (MJFF). Today's press release reveals...

“Human-on-a-Chip” OOC to revolutionise preclinical

New system of linked mini-organs heralds a new era of comprehensive drug testing that is faster and more efficient than anything seen before. OOC...

Biosens raising £5m to support commercialisation

Start-up targets cell senescence therapies and near-term opportunities in advanced cosmetics market. The market for the development of anti-senescence therapeutics is on fire and we’ve...

Five Alarm Bio targets Alzheimer’s and skin aging

Stealthy anti-aging start-up kicks-off £2.6m fundraise to target both Alzheimer's and advanced cosmetics. Many of the companies working in the Longevity sector are playing their...

AgeX collaborates with Japanese biopharma

AgeX Therapeutics has announced a research collaboration with an as-yet-undisclosed Japanese biopharm company to further the development of its immunotolerance technology platform. AgeX is focused...

Singapore to start human Longevity studies

Prof Brian Kennedy: "One of the reasons I came to Singapore is that the government recognises the problem of aging." In this second part of...

Revel Pharmaceuticals’ seed round for anti-aging drugs

Top Yale lab spawns new company focused on development of glucosepane-cleaving drugs. San Francisco based biotech start-up Revel Pharmaceuticals has announced itself to the...

Prof Brian Kennedy: Talking biomarkers and interventions

“We're not trying to make billionaires live longer, we're trying to make everybody live longer.” When it comes to thought leaders in the Longevity sector,...

Talking pipeline with resTORbio’s Joan Mannick

While Phase 3 trial of RTB101 for respiratory illness did not meet primary endpoint, company presses-on with Parkinson’s trial for TORC1 inhibitor: Results expected...

It’s all in the numbers; small sets of numbers

AI start-up NetraMark targets $3 million seed round while identifying that an exciting repurposing candidate has potential for indication expansion into Longevity. “I won’t tell you...

Identification of age-related protein waves in blood

New proteomic discoveries reveal a link between levels of certain proteins in human plasma and aging. The field of aging-targeting therapeutics is rapidly evolving. The...

NetraMark and Juvenescence extend collaboration

Partnership sees AI platform expanded into drug repurposing and discovery. Canadian AI technology firm NetraMark yesterday announced the extension of its NetraPharma collaboration agreement with...

AI innovators prefer autonomy to big pharma

AI drug discovery is hot; researchers expect it to reach US$20 billion in the next five years. Advances in AI see it is being used...

Biomarkers of aging: AI discovery to therapy

Deep aging clocks – the emergence of Al-based biomarkers of aging and Longevity and their implications in the development of therapeutic restorative interventions that...

Out of stealth and probing the dark side of DNA

Ervaxx CEO looks to raise new funding in 2020 to continue momentum on top of $17.5m Series A. Earlier this month, we reported on UK...

Rejuvenation: If I could turn back time …

Bioquark looks to nature for the answers to regeneration and rejuvenation. Last week, the BBC reported on the plight of axolotls in Mexico City, which...

Longevity biomarkers mapped out in new report

Aging Analytics Agency profiles more than 50 biomarkers related to age-related diseases and syndromes. Earlier this week, attendees at the AI for Longevity Summit at...

SENS’ Underdog launches novel CVD treatment

SENS Research Foundation launches Underdog - a new therapeutic approach to cardiovascular disease (CVD). According to the World Health Organisation (WHO), cardiovascular diseases is the...

Latest articles

Global investment consortium slated to back Telocyte into Phase 1

Telomerase therapy ready for human Alzheimer’s trials. “There have been more than 400 registered trials for Alzheimer's and, by global consensus, every single one has...

Longevity 2020: shaping-up nicely

Over 45 confirmed speakers for this 5-day online event and a big thank you for your interest. We're moving fast! Longevity 2020 started just over...

Telomeres on repeat to inhibit inflamm-aging

Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres. Inflammation is a double-edged sword; while it is necessary...

Join me at my 100th birthday party in 2049!

We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years. One of the speakers at this month’s...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.